In:
The Journal of Immunology, The American Association of Immunologists, Vol. 166, No. 7 ( 2001-04-01), p. 4612-4619
Abstract:
The recent identification of tumor Ags as potential vaccines has prompted the search for efficient adjuvants and delivery systems, especially in the case of peptide-based vaccination protocols. Here, we investigated the adjuvant potential of the recombinant 40-kDa outer membrane protein of Klebsellia pneumoniae (P40) for specific CTL induction. We studied the CTL response induced in HLA-A*0201/Kb transgenic mice immunized with peptides derived from two melanoma-associated differentiation Ags, the HLA-A*0201-restricted decapeptide Melan-A26–35 substituted at position 2 and the Kb-restricted tyrosinase-related protein 2181–188 T cell epitope. We found that both peptides are able to generate a specific CTL response when mixed with the protein in the absence of conventional adjuvant. This CTL response is a function of the amount of P40 used for immunization. Moreover, the CTL response generated against the tyrosinase-related protein 2181–188 peptide in presence of P40 is associated with tumor protection in two different experimental models and is independent of the presence of CD4+ T lymphocytes. Thus, the recombinant bacterial protein P40 functions as a potent immunological adjuvant for specific CTL induction.
Type of Medium:
Online Resource
ISSN:
0022-1767
,
1550-6606
DOI:
10.4049/jimmunol.166.7.4612
Language:
English
Publisher:
The American Association of Immunologists
Publication Date:
2001
detail.hit.zdb_id:
1475085-5
Permalink